NRx Pharmaceuticals got some good news from the FDA and its shareholders are happy as NRXP stock enjoys a day of impressive gains. Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday By William White, InvestorPlace Writer Sep 7, 2021 It's been a long holida...
NRX Pharmaceuticals, Inc. 道琼斯:44910.650.42% 纳斯达克:19218.170.83% 标普500:6032.380.56% 休盘中11月29日 14:37(美东) 最近浏览 NASDAQ:NRXP实时 1.310.021.55%2024-11-29 13:00:00 今开:1.30 昨收:1.29 今日区间:1.29-1.33 52周区间:1.10-7.33...
HC Wainwright & Co.:重申NRX Pharmaceuticals(NRXP.US)评级,由买入调整至买入评级, 目标价由19.00美元调整至19.00美元。 NRX Pharmaceuticals(NRXP.US)公司简介:NRX Pharmaceuticals Inc 是一家临床阶段的小分子制药公司,开发并计划销售用于治疗中枢神经系统疾病和危及生命的肺部疾病的新型疗法。 该公司宣布了新型冠状病...
Stock Screener Earnings Calendar Sectors Nasdaq Search Ticker | NRXPU.S.: Nasdaq Watchlist You must be logged in to create alerts After Hours Last Updated:Nov 22, 2024 7:29 p.m.ESTDelayed quote $1.2000 -0.06-4.76% After Hours Volume:220 ...
NRx Pharmaceuticals today announced positive data from its ZYESAMI™ (Aviptadil) Expanded Access Protocol (EAP).